What Mendelics does

Mendelics is a Brazilian genomic analysis laboratory founded in 2012 that specializes in genetic diagnostic testing using Next-Generation Sequencing (NGS) technology. The company operates an integrated testing platform spanning Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), and over 20 specialty-specific gene panels covering hereditary cancers, neurological disorders, cardiomyopathies, mitochondrial diseases, immunodeficiencies, retinopathies, hearing loss, and other conditions. Its flagship products include the Exoma Mendelics (described as having the highest diagnostic rate in the market) and the Teste da Bochechinha, a newborn screening panel analyzing 500+ rare disease genes. The company runs proprietary AI-powered software for variant interpretation, trained on what it describes as the largest Brazilian and Latin American genetic variant database built from 100,000+ tests performed.

Mendelics monetizes genetic testing services on a per-test (pay-as-you-go) basis, billed through private health insurance operators (30+ partners including Bradesco Saúde, SulAmérica, Unimed, Amil, Allianz Saúde), the SUS public healthcare system, or direct payment. The go-to-market motion is sales-led, targeting healthcare professionals — geneticists, oncologists, neurologists, cardiologists, and other specialists — who order tests on behalf of patients, supplemented by direct patient outreach via WhatsApp and phone. Sample collection occurs at a single in-person site in São Paulo (Av. Nove de Julho, 4346), with technical operations handled at a separate Technical-Operational Center (Av. Braz Leme).

The company is structured as a Sociedade Anônima (Mendelics Análise Genômica S.A.) with 251-500 employees and is headquartered in São Paulo, Brazil. It holds the only CAP accreditation among Brazilian genomic laboratories, alongside PALC, CLIA, ISO 15189, and ISO/IEC 27001:2022 certifications. The founder and CEO is David Schlesinger, with Dr. Fernando Kok serving as Technical Responsible (CRM-SP 32.255). Operations have expanded beyond Brazil to include Colombia, positioning Mendelics as the first and largest dedicated genomic analysis laboratory in Latin America.

Name

Mendelics

Legal name

Mendelics Análise Genômica S.A.

Website

https://mendelics.com.br

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

251–500 employees

Short description

Mendelics is a Brazilian genomic analysis laboratory founded in 2012 that provides Next-Generation Sequencing-based genetic diagnostic testing, including Whole Exome Sequencing, hereditary cancer panels, and newborn screening. It serves healthcare providers, patients, and the SUS public health system via 30+ insurance networks, using proprietary AI software trained on the largest Latin American variant database.

Ownership category

akta.pro rank

Product category

Clinical Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Genetic testing services
• Clinical genomic diagnostics
• Next-generation sequencing
• Hereditary cancer panels
• Newborn genetic screening

Headquarters

HQ city

Vila Mariana

HQ country

Brazil

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Genetic Testing Services: Laboratory genetic testing services including Whole Exome, gene panels, SNP arrays, and MLPA tests. Revenue generated through patient specimens ordered by healthcare providers, billed via insurance or direct payment.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Mendelics is a Brazilian clinical laboratory that performs genomic diagnostic testing services using Next-Generation Sequencing (NGS), Whole Exome Sequencing, Whole Genome Sequencing, SNP arrays, and MLPA. Tests are ordered by healthcare professionals across cardiology, neurology, oncology, and rare disease specialties, with results interpreted by proprietary AI-powered software and supported by the largest Brazilian/Latin American variant database. Services are billed through private health insurance, SUS (public system), or direct payment, with sample collection at the São Paulo laboratory.

Product overview

Mendelics is a genomic analysis company offering a comprehensive portfolio of genetic testing services centered on Next-Generation Sequencing (NGS) technology. The core product is the Exoma Mendelics (Whole Exome Sequencing), described as having the highest diagnostic rate in the market. The company provides genetic tests across multiple medical specialties including cardiology, dermatology, endocrinology, gastroenterology, medical genetics, hematology, nephrology, neurology, ophthalmology, oncology, otolaryngology, and women's health. Key offerings include the Teste da Bochechinha (newborn screening for 500+ rare diseases), hereditary cancer panels including the Gold Standard Panel analyzing 100 cancer predisposition genes with PRS for breast cancer, specialized panels for epilepsy, neuropathies, cardiomyopathies, mitochondrial diseases, immunodeficiencies, and various expansion disorder tests. The company employs proprietary AI-powered software for genetic data analysis, which won the MIT innovation award. Tests are available for both private patients and public healthcare institutions (SUS), with coverage through major Brazilian health insurance providers.

Differentiator

Problem solved

Functional benefit

Brands

• Teste da Bochechinha: A genetic test that analyzes over 500 genes for rare diseases in asymptomatic babies, offered as a preventive screening panel.

Products and services

• Exoma Mendelics (Whole Exome Sequencing) Whole Exome Sequencing (WES) examination analyzing nearly all exons of 20,000 human genes plus copy number variations (CNVs) and mitochondrial DNA in a single test. Includes analysis of point mutations, indels, CNVs, and mitochondrial DNA. Marketed as having the highest diagnostic rate in the market with an estimated delivery time of 35 days. Targets healthcare providers across multiple specialties seeking comprehensive genomic diagnosis.
• Teste da Bochechinha (Newborn Genetic Screening) Newborn genetic screening test analyzing more than 500 genes that can cause rare diseases with early manifestation and available treatment. Covers treatable diseases across multiple classes including inborn errors of metabolism, neurological, immunological, hematological, endocrine, renal, hepatic, gastrointestinal, and skeletal diseases. Recommended for screening rare diseases in asymptomatic babies preventively and is offered as a dedicated sub-brand.
• Painel de C\u00e2ncer Heredit\u00e1rio Padr\u00e3o-Ouro (Gold Standard Hereditary Cancer Panel) Advanced hereditary cancer genetic test using NGS to identify pathogenic variants in 100 genes most relevant for cancer predisposition. Includes Polygenic Risk Score (PRS) for female breast cancer validated in the Brazilian population, promoter region analysis of all panel genes, and coverage of all pathogenic variants in exons and 99.9% of intronic variants registered in ClinVar, with detailed focus on BRCA1 and BRCA2.
• Exames Gen\u00e9ticos para C\u00e2ncer (Genetic Tests for Cancer Suite) Comprehensive suite of genetic tests for hereditary cancer risk assessment, including NGS panels for breast and ovarian cancer (37 genes, 20-day delivery), colorectal cancer (42 genes including PMS2), expanded melanoma and skin cancer panels, and multi-cancer predisposition testing. Targeted at oncologists, geneticists, and other specialists managing hereditary cancer risk in patients.
• Painel NGS para Triagem de Expans\u00f5es (NGS Panel for Expansion Screening) Innovative NGS-based panel to detect nucleotide repeat expansions causing 7 neurological diseases: Spinocerebellar Ataxia (SCA1, SCA2, SCA3), Huntington's Disease, Huntington-like Disease 2, Spinal and Bulbar Muscular Atrophy (Kennedy Disease), and Myotonic Dystrophy Type 1. Uses differentiated NGS methodology combined with advanced data analysis algorithms to overcome limitations of conventional NGS sequencing.
• Triagem de Portador de Muta\u00e7\u00f5es de Doen\u00e7as Recessivas e Ligadas ao X (Carrier Screening) Carrier screening test identifying mutations in genes related to autosomal recessive and X-linked diseases for genetic counseling of couples with increased reproductive risk. Supports family planning and reproductive genetic counseling.
• Sequenciamento do Genoma Completo (Whole Genome Sequencing) Most comprehensive Next-Generation Sequencing (NGS) test analyzing intronic and exonic regions of more than 20,000 human genes, non-coding regions (including regulatory regions), copy number variations (CNVs), and mitochondrial DNA. Estimated delivery time is 60 days. Targeted at complex diagnostic cases requiring the most comprehensive genomic analysis available.
• Array (SNP Array de Alta Densidade) High-density SNP array investigating thousands of regions in the human genome to identify copy number variations (CNVs) including deletions and duplications. Used for diagnosing patients with suspected microdeletion and microduplication syndromes.
• Painel de Epilepsias (Epilepsy Panel) NGS panel analyzing genes associated with epilepsy conditions, particularly epileptic encephalopathies and drug-resistant epilepsies. Includes analysis for Dravet syndrome, neuronal ceroid lipofuscinoses, tuberous sclerosis, and other genetic epilepsies. Targeted at neurologists managing pediatric and adult epilepsy cases.
• Painel de Miocardiopatias (Cardiomyopathy Panel) NGS panel analyzing genes most frequently associated with different forms of hereditary cardiomyopathy including dilated cardiomyopathies, hypertrophic cardiomyopathies, ventricular non-compaction, and cardiac arrhythmias. Targeted at cardiologists diagnosing inherited cardiac conditions.
• An\u00e1lise Polig\u00eanica (PRS) para C\u00e2ncer de Mama (Polygenic Risk Score for Breast Cancer) Polygenic Risk Score (PRS) analysis for breast cancer, validated for the Brazilian population. Assesses genetic predisposition beyond single gene mutations, providing a multi-gene risk assessment for breast cancer. Available as part of the Gold Standard Hereditary Cancer Panel offering.
• S\u00edndrome do X-Fr\u00e1gil (FMR1 Expansion Test) Molecular test for FMR1 gene expansion diagnosing Fragile X Syndrome, the leading genetic cause of intellectual disability after Down syndrome. Targeted at neurologists and geneticists diagnosing intellectual disability and developmental delay.
• Painel de Dem\u00eancias e Parkinson (Dementia and Parkinson Panel) NGS panel analyzing over 60 genes involved in early and/or familial forms of Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, and Alexander Disease. Targeted at neurologists managing early-onset and familial neurodegenerative conditions.
• MLPA Tests (Multiple Gene Panels) Multiple MLPA (Multiplex Ligation-dependent Probe Amplification) tests for specific genes including ATM, APC, BRCA1, BRCA2, BAP1, CDH1, BRIP1, CDKN2A, CDK4, MEN1, CHEK2, MLH1, MET, MSH6, MSH2, PMS2, PALB2, MUTYH, RB1, PTEN, SDHB, RET, TP53, STK11, and WT1 for detection of microdeletions or microduplications. Used as targeted confirmation tests for hereditary cancer syndromes.

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core.

• Bradesco SaúdecoreChannel Partner/ Reseller/ DistributorHealth insurance network partnership allowing covered patients to access Mendelics genetic testing services through their insurance plan.
• SulAméricacoreChannel Partner/ Reseller/ DistributorHealth insurance network partnership for genetic testing services coverage.
• UnimedcoreChannel Partner/ Reseller/ DistributorMajor Brazilian health insurance operator network partnership for genetic testing coverage.
• AmilcoreChannel Partner/ Reseller/ DistributorHealth insurance network partnership for genetic testing services under insurance coverage.
• Allianz SaúdecoreChannel Partner/ Reseller/ DistributorHealth insurance network partnership for genetic testing coverage.
• SUS (Sistema Único de Saúde)coreChannel Partner/ Reseller/ DistributorPublic healthcare system partnership providing genetic testing services to Brazilian public healthcare patients.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Myriad Genetics: Pioneer in hereditary cancer genetic testing (BRACAnalysis, myRisk). Comparable to Mendelics' hereditary cancer panels and BRCA1/BRCA2 focus, with established international presence and similar sales-led motion through clinicians.
• Natera: US molecular diagnostics company specializing in cell-free DNA testing, reproductive health, and oncology genomics. Comparable in NGS-based testing infrastructure and direct-to-clinician sales motion, with growing international footprint.
• Color Genomics: US-based genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomic panels at accessible price points. Comparable in NGS panel structure and emphasis on clinician-driven hereditary risk testing.
• Centogene: Germany-based rare disease genetic diagnostics company with focus on exome/genome sequencing and proprietary biomarker interpretation. Comparable in rare disease focus and population-level variant database approach, though with European/EMEA geographic center.
• Ambry Genetics: Clinical genetics laboratory offering exome sequencing, hereditary cancer panels, and rare disease diagnostics. Directly comparable to Mendelics' Exoma Mendelics product and comprehensive panel strategy, with CAP/CLIA certifications.
• Invitae (now Labcorp Genetics): US-based clinical genetic testing lab offering hereditary cancer panels, exome sequencing, and reproductive health tests. Directly comparable to Mendelics in NGS-based hereditary disease and cancer testing, with global expansion ambitions into Latin America.

Broad incumbents

• Grupo Fleury: Major Brazilian diagnostic medicine company with extensive lab network across Brazil. Comparable in clinical diagnostics scale, SUS/insurance coverage, and growing hereditary/genomic testing portfolio competing directly with Mendelics.
• SYNLAB: European-headquartered clinical diagnostics leader with expanding Latin American footprint through acquisitions. Overlaps with Mendelics in clinical lab services and genetic testing, but operates as a broad multi-country incumbent.
• NeoGenomics: US-listed clinical oncology and genetic testing lab with broad specialty and hospital-channel footprint. Overlaps with Mendelics in hereditary cancer and molecular diagnostics but operates as a multi-service incumbent rather than genomics specialist.
• Dasa: Brazil's largest medical diagnostics company, operating a nationwide network of clinical labs with growing genomic medicine offering. Comparable as a Brazil-headquartered diagnostic incumbent with overlapping NGS and genetic testing ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• Xx.com/mendelics
• Facebookfacebook.com/Mendelics
• LinkedInlinkedin.com/company/mendelics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mendelics